In a multicenter trial, the effect of a commercially available combination of autologous keratinocytes (3-6 x 10(6)/mL) with fibrin sealant (Tissucol Duo S Immuno, Baxter Hyland Immuno) on the healing of recalcitrant venous leg ulcers (duration >3 months) was compared with standard care. The primary endpoint was time to healing, and the secondary endpoint was number of healed ulcers in both groups. Both groups received compression therapy with short-stretch bandages. Forty-four (38.3%) of the 116 patients who had BioSeed-S treatment achieved complete healing of the target ulcer compared with 24 (22.4%) of 109 patients who received standard treatment. The advantage for treatment with BioSeed-S over standard treatment was statistically significant (chi-square test: p=0.0106). Time to complete healing of ulcers: the log-rank test for equality over strata revealed a superiority of treatment with BioSeed-S+compression (median: 176 days) over compression+standard care (median >201 days) (p<0.0001). This study, to date the largest multicenter study with autologous keratinocytes, provides evidence for its efficacy in the treatment of patients with therapy-resistant chronic venous leg ulcers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1524-475X.2007.00231.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fibroadipose Vascular Anomaly [FAVA] - A Distinct Entity and Not Just a Malformation!
J Orthop Case Rep
December 2024
Department of Orthopaedic Oncology, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India.
Introduction: Fibroadipose vascular anomaly (FAVA) was described in 2014 as a distinct entity characterised by intramuscular replacement with fibro fatty tissue along with complex vascular malformation, phelbectesia, venous thrombosis and lymphatic involvement. Somatic mutations in the PIK3CA gene are detected in most lesions which diagnosed the FAVA in our report and occurrence of this mutation seems to be sporadic.
Case Report: Common presentation is a painful intramuscular swelling in young women - as was the presentation here in an 11 year girl with the swelling of the right thigh.
High-Flow Arteriovenous Malformations: Treatment Using a Venous Approach.
Semin Intervent Radiol
August 2024
University of Chicago Medicine, Chicago, Illinois.
High-flow arteriovenous malformations (AVMs) are among the rarest and most recalcitrant lesions in medicine. Patients with these anomalies are best managed longitudinally in tertiary referral centers by dedicated multidisciplinary teams that include surgeons, dermatologists, hematologists, geneticists, and interventional radiologists. A significant percentage of these lesions cannot be cured per se and intervention can worsen symptoms or preclude effective future embolization.
View Article and Find Full Text PDFAnalysis of computed tomography venography for the diagnosis and endovascular treatment of iliac venous compression syndrome with venous leg ulcers: a retrospective study.
Sci Rep
September 2024
Department of Vascular and Endovascular Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Shijiazhuang, Hebei, 050031, People's Republic of China.
Article Synopsis
- Iliac vein compression syndrome (IVCS) is caused by chronic pressure on the iliac vein, leading to potential complications like venous leg ulcers (VLU), but the diagnostic role of computed tomography venography (CTV) is still being explored.
- A study analyzed the medical records of 62 patients, finding that CTV delivered more thorough information than other imaging methods and that female sex and older age are significant risk factors for IVCS.
- The research indicated that patients with IVCS who received stenting showed notable improvements in both clinical symptoms and ulcer healing rates, suggesting that stenting could be a beneficial treatment option.
Patency rates following treatment with the WRAPSODY™ Cell-Impermeable Endoprosthesis for recalcitrant renal access circuit dysfunction: Results from a tertiary Australian centre.
Vascular
August 2024
Marketing Department, Merit Medical Systems, Inc, South Jordan, UT, USA.
Objective: To describe clinical outcomes associated with the use of the WRAPSODY Cell-Impermeable Endoprosthesis at a tertiary center in Western Australia.
Methods: Patients with recalcitrant occlusive disease in the venous outflow of their arteriovenous access circuits were treated with WRAPSODY. Patients were prospectively followed up to 12-month post-procedure.
VEXAS syndrome.
Int J Hematol
May 2024
Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 3-9 Fuku-Ura, Kanazawa-Ku, Yokohama, 236-0004, Japan.
Article Synopsis
- VEXAS syndrome is a newly discovered autoinflammatory disease in adults caused by mutations in the UBA1 gene, leading to immune system activation and symptoms like fever and joint inflammation.
- The syndrome is associated with blood disorders and specific blood cell changes, which can serve as indicators for diagnosing UBA1 mutations in symptomatic patients.
- Treatment options are limited, but hematopoietic stem cell transplantation is the only potential cure, particularly for younger, healthier patients experiencing severe symptoms or complications.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!